Biogen Inc vs VF Corp — how do they compare? Biogen Inc trades at $202.7 (market cap $30.13B), while VF Corp trades at $14.9 (market cap $5.81B). The key difference: Biogen Inc is far larger — about 5.2× VF Corp's market cap, and VF Corp pays a 2.44% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | VFC | |
|---|---|---|
Market Cap | $30.13B | $5.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $21.55 |
52-Week Low | $128.93 | $12.21 |
Enterprise Value | $37.20B | $10.09B |
Dividend Yield | — | 2.44% |
Trailing returns across standard periods
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →